明尼阿波利斯（路透社健康专栏）12月21日电—据《变态反应，高血压及病理学年刊》月刊11月刊一篇报道，舌下减敏替代疗法（SLIT）替代疗法花粉诱发的消化道过敏收效高。“来顺利进行SLIT减少气喘的并发症及口服消费，减轻观念开销，”意大利Genoa的大学Giovanni Passalacqua芝加哥大学问道。“先前之前有更进一步施用替代疗法减轻观念负担，但这是首次对实用性替代疗法（SLIT）顺利进行严格评估的结果。”Passalacqua芝加哥大学及其同事们对花粉诱发的过敏性气喘和高血压治果顺利进行研究课题，评估来顺利进行SLIT结合标准规范替代疗法及分开来顺利进行标准规范替代疗法的开销及。研究课题人员报道，SLIT使63.1%的病症症状优化，并传染病51.8%的病症出现高血压，而分开领域标准规范替代疗法仅仅使23.2%的病症症状优化，传染病28.9%的病症出现高血压。而且同标准规范替代疗法相比较，SLIT的必要及间接要花费除此以外增高：SLIT病症替代疗法的上都要花费小于各地区卫生保健系统预测的4周内分开口服替代疗法要花费，并且小于观念公众预测的2周内分开口服替代疗法要花费。“SLIT并很难都是更进一步施用替代疗法的巨头，” Passalacqua芝加哥大学理解问道，“而是将其作为替代疗法分析方法的另一自由选择。它仅有的特性在于其最优的安全性和病症的易给予性。”“SLIT在美国从未正式领域，尽管一些变态反应专家领域它（并且取得了失望的结果），” Passalacqua芝加哥大学问道。“欧洲情况仅仅不同，SLIT在很多各地区中广泛领域（如意大利，丹麦，法国，西班牙，葡萄牙，埃及及匈牙利）。”当前的疑虑是SLIT从未取得FDA的批准，“Passalacqua芝加哥大学必要道。“受到FDA支持的临床研究课题正在顺利进行中，并有望取得批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma & Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.
撰稿：蓝色幻想
撰稿： 张靖相关新闻
相关问答
